Could 13, 2022
1 min learn
Wysa introduced it has acquired breakthrough gadget designation from the FDA for its synthetic intelligence-based digital psychological well being conversational agent for adults with persistent musculoskeletal ache, melancholy and nervousness.
The gadget delivers cognitive behavioral remedy via a smartphone-based conversational agent, which reduces signs of melancholy and nervousness whereas additionally lowering ache interference and bettering bodily features.
“We’re thrilled to realize this significant designation from the FDA and sit up for working carefully with the company to proceed growth of AI-based cognitive behavioral remedy,” Jo Aggarwal, Wysa CEO, mentioned in a launched assertion.
The FDA designation follows an impartial, peer-reviewed scientific trial, which confirmed that the conversational agent was efficient for managing persistent ache and related melancholy and nervousness. The trial confirmed it was simpler than commonplace orthopedic care and similar to in-person psychological counseling.
“Our mission is to assist these in want of help with an at all times accessible platform, and through these difficult occasions it’s extra essential than ever to offer psychological well being choices,” Aggarwal mentioned.